Can Ruxolitinib cure myelofibrosis?

The JAK1/JAK2 inhibitor Ruxolitinib is currently the only drug approved for the treatment of myelofibrosis. Primary myelofibrosis is a myeloproliferative tumor clinically characterized by myelofibrosis, progressive anemia and extramedullary hematopoiesis, usually manifested by splenomegaly. Myelofibrosis may also occur as a symptom of disease progression in other myeloproliferative neoplasms, particularly polycythemia vera (PV) and essential thrombocythemia (ET).

Based on results from twoPhase 3 trials comparingruxolitinib tablets with placebo and best available therapy in the treatment of primary or secondary myelofibrosis. In these pivotal trials, ruxolitinib rapidly improved splenomegaly, disease-related symptoms, quality of life, and prolonged survival compared with placebo and usual care. During treatment, the patient experienced significant improvement in splenomegaly and symptoms shortly after starting ruxolitinib tablets . With the prolongation of treatment time, the patient's JAK2 V617F allele load was significantly reduced, and myelofibrosis subsided after ruxolitinib treatment for about 3 years.

Ruxolitinib tabletsThe original drug has been launched in China and is included in the scope of Class B medical insurance. It is limited to patients who meet the indications. Specification The price of each box of 5mg*60 tablets may be around RMB 3,000. The Turkish version of ruxolitinib tablets listed overseas, Specifications20mg*56 tablets, may be priced around RMB 8,000 per box (the price may fluctuate due to exchange rates). There are also ruxolitinib tablets produced in other countries. For example, the price of 5mg*50 tablets produced by Bangladesh Yaopin International may be around 1,400 yuan per box (the price may fluctuate due to exchange rates). Its pharmaceutical ingredients are basically the same as those of domestic and foreign original drugs.